Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab
D4880C00003
Phase 2 small_molecule active
Quick answer
Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab for unresectable pleural or peritoneal malignant mesothelioma is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- unresectable pleural or peritoneal malignant mesothelioma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active